Unexplained muscle weakness and fatigue? Signs it might be time to talk to your doctor about IMAAVY® (nipocalimab-aahu)
Please see the full Prescribing Information and Patient Information for IMAAVY and discuss any questions you have with your doctor.
TL;DR – Muscle fatigue, changes in vision, and muscle weakness can be common symptoms of generalized myasthenia gravis (gMG).i Continue reading to explore common symptoms of gMG and learn more about IMAAVY (nicpocalimab-aahu) as a treatment for patients 12 and older living with anti-AChR or anti-MuSK antibody-positive gMG.ii Talk to your doctor about potential side effects such as respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms or if IMAAVY may be right for you.ii
If you’ve been experiencing muscle fatigue, changes in vision, trouble speaking, or muscle weakness, these can be common symptoms of generalized myasthenia gravis (gMG).i gMG is a rare autoimmune neuromuscular disease that interrupts communication between the nerves and muscles, causing muscle weakness and tiredness.

Recognizing gMG symptoms early is the critical first step toward getting an accurate diagnosis and an effective disease management plan, as gMG affects both children and adults.i Below is a look at common symptoms of gMG and how IMAAVY may be a treatment to discuss with your doctor.
1Myasthenia Gravis Clinical Overview. Access at: https://myasthenia.org/Professionals/Clinical-Overview-of-MG#DIAGNOSTIC
2IMAAVY [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
| gMG Symptomsi | Results from the IMAAVY Clinical Study |
|---|---|
| Significant improvement in daily function† and muscle weakness‡ based on the MG-ADL and QMG scales measured in a 24-week clinical study.ii |
†Measured using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. In a clinical study, MG-ADL improved on average by 4.7 points with IMAAVY + current gMG treatment and 3.3 points with placebo + current gMG treatment from baseline to Weeks 22, 23 and 24.ii,3
‡Measured using the Quantitative Myasthenia Gravis (QMG) scale, which assesses muscle weakness based on 13 items. QMG total score improved on average by 4.9 points with IMAAVY + current gMG treatment and 2.1 points with placebo + current gMG treatment from baseline to Weeks 22 and 24.ii,iii
IMAAVY® is not for everyone; only your healthcare provider can decide if it’s right for you. Do not use if you are allergic to IMAAVY®. Reactions have included angioedema and anaphylaxis. IMAAVY® is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY® should not receive live vaccines. Please read the Important Safety Information below and the Medication Guide for IMAAVY® to learn more about these and other risks associated with IMAAVY®. Discuss any questions you have with your healthcare Provider.
3Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105–116. doi:10.1016/S1474-4422(24)00498-8
1. Is your jaw getting tired and are you having trouble speaking?
What You Might Experience
Do you start eating a meal normally, only for your facial muscles to fatigue halfway through? Have you noticed you are having trouble talking, climbing the stairs, or getting up from a chair?i
How IMAAVY May Help
In a clinical study, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale was used to assess the impact of gMG on 8 daily-function items that are typically affected in gMG., MG-ADL total score improved on average by 4.7 points with IMAAVY + current gMG treatment and 3.3 points with placebo + current gMG treatment from baseline to Weeks 22, 23 and 24.ii,iii
The Quantitative Myasthenia Gravis (QMG) scale was also used to assess muscle weakness based on 13 items.v QMG total score improved on average by 4.9 points with IMAAVY + current gMG treatment and 2.1 points with placebo + current gMG treatment from baseline to Weeks 22 and 24.ii,iii
In the study, patients were given IMAAVY + their current gMG treatment or placebo + their current gMG treatment. Current therapies included acetylcholinesterase inhibitors (85%), steroids (66%), or non-steroidal immunosuppressive therapies (54%), taken together or separately.ii

Take Action:If you are experiencing speech or swallowing changes, track your symptoms to share with your neurologist.
2. What causes changes in vision?
What You Might Experience
Vision changes can be one of the first signs of generalized myasthenia gravis. Approximately half of people who develop gMG experience eye muscle weakness first, which can include drooping eyelids, double vision, or blurred vision.i
How IMAAVY May Help
In a clinical study, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale was used to assess the impact of gMG on 8 daily-function items that are typically affected in gMG.iv,v MG-ADL total score improved on average by 4.7 points with IMAAVY + current gMG treatment and 3.3 points with placebo + current gMG treatment from baseline to Weeks 22, 23 and 24.ii,iii
The Quantitative Myasthenia Gravis (QMG) scale was also used to assess muscle weakness based on 13 items.v QMG total score improved on average by 4.9 points with IMAAVY + current gMG treatment and 2.1 points with placebo + current gMG treatment from baseline to Weeks 22 and 24.ii,iii
In the study, patients were given IMAAVY + their current gMG treatment or placebo + their current gMG treatment. Current therapies included acetylcholinesterase inhibitors (85%), steroids (66%), or non-steroidal immunosuppressive therapies (54%), taken together or separately.ii
4Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487
5Muppidi S, Silvestri NJ, Tan R, et al. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle & Nerve. 2022;65(6):630-639. doi:10.1002/mus.27476
3. Why do you feel tired and fatigued after normal activity?
What You Might Experience
From heavy legs after climbing a short flight of stairs to arms that feel too weak to brush your hair or lift a grocery bag, gMG muscle fatigue that can make everyday activities challenging for both adults and children (ages 12+).i

How IMAAVY May Help
In a clinical study, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale was used to assess the impact of gMG on 8 daily-function items that are typically affected in gMG.iv,v MG-ADL total score improved on average by 4.7 points with IMAAVY + current gMG treatment and 3.3 points with placebo + current gMG treatment from baseline to Weeks 22, 23 and 24.ii,iii
The Quantitative Myasthenia Gravis (QMG) scale was also used to assess muscle weakness based on 13 items.v QMG total score improved on average by 4.9 points with IMAAVY + current gMG treatment and 2.1 points with placebo + current gMG treatment from baseline to Weeks 22 and 24.ii,iii
In the study, patients were given IMAAVY + their current gMG treatment or placebo + their current gMG treatment. Current therapies included acetylcholinesterase inhibitors (85%), steroids (66%), or non-steroidal immunosuppressive therapies (54%), taken together or separately.ii

Explore how IMAAVY was studied in both adults and adolescents here.
4. Are you looking for a consistent dosing schedule?
If you're looking for a consistent dosing schedule, talk with your healthcare provider.
How IMAAVY May Help
IMAAVY is the first neonatal fragment crystallizable receptor (FcRn) blocker for gMG with a consistent dosing schedule every 2 weeks that you can plan around.ii
The most common side effects in people with gMG treated with IMAAVY include respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms.ii These are not all the possible side effects of IMAAVY. Discuss any questions you have with your healthcare provider.

Next Steps: Ready to take the next step? Prepare for your neurology appointment by downloading the IMAAVY brochure, your all-in-one guide to IMAAVY clinical study results, safety, dosing, and more.
WHAT IS IMAAVY® (nipocalimab-aahu)?
IMAAVY is a prescription medicine used to treat adults and children 12 years of age and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
It is not known if IMAAVY is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about IMAAVY® (nipocalimab-aahu)?
IMAAVY is a prescription medicine that may cause serious side effects, including:
Infections. IMAAVY may increase your risk of infections, including serious infections. If you have an infection, your healthcare provider will treat your infection or delay your infusion until your infection is gone. Tell your healthcare provider right away if you have any of the following infection symptoms:
fever
chills
shivering
cough
sore throat
fever blisters
burning when you urinate
trouble breathing
Allergic (hypersensitivity) reactions can happen during or up to a few weeks after your IMAAVY infusion. Tell your healthcare provider and get emergency medical help right away if you get any of these symptoms during or after your IMAAVY infusion:
a swollen face, lips, mouth, tongue, or throat
trouble swallowing or breathing
hives
itchy rash
chest pain or tightness
Infusion-related reactions. Tell your healthcare provider right away if you get any of these symptoms during or within a few days after your IMAAVY infusion:
headache
rash
nausea
fatigue
dizziness
chills
flu-like symptoms
redness of skin
Do not receive IMAAVY if you have a history of a severe allergic reaction to nipocalimab-aahu or any of the ingredients in IMAAVY. Reactions have included angioedema and anaphylaxis. Refer to the Patient Information section of the Prescribing Information for a complete list of ingredients in IMAAVY.
Before receiving IMAAVY, tell your healthcare provider about all of your medical conditions, including if you:
have had an allergic reaction to IMAAVY.
have or had any recent infections or symptoms of infection.
have or had shingles (herpes zoster) or mono (mononucleosis caused by Epstein-Barr virus).
have recently received or are scheduled to receive an immunization (vaccine). People who take IMAAVY should not receive live vaccines.
are pregnant or plan to become pregnant. It is not known if IMAAVY will harm your unborn baby.
Pregnancy Safety Study. There is a pregnancy safety study for IMAAVY. If IMAAVY is given during pregnancy or you become pregnant while receiving IMAAVY, your healthcare provider should report IMAAVY exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com.
are breastfeeding or plan to breastfeed. IMAAVY can pass into your breast milk. It is not known if IMAAVY will harm your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with IMAAVY.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of IMAAVY?
IMAAVY may cause serious side effects. See “What is the most important information I should know about IMAAVY?”
The most common side effects in people with gMG treated with IMAAVY include: respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms.
These are not all the possible side effects of IMAAVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see the full Prescribing Information and Patient Information for IMAAVY and discuss any questions you have with your doctor.
Dosage Form and Strengths: IMAAVY is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.
cp-509746v5

© Johnson & Johnson and its affiliates 2026 11/26 cp-608402v1



